NCT02851277View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

December 6, 2018

Study Completion Date

December 6, 2018

Conditions
Peanut Allergy
Interventions
DRUG

ASP0892 Intradermal

Intradermal injection

DRUG

ASP0892 Intramuscular

Intramuscular injection

DRUG

Placebo Intradermal

Intradermal injection

DRUG

Placebo Intramuscular

Intramuscular injection

Trial Locations (8)

21287

Site US10001, Baltimore

27599

Site US10003, Chapel Hill

45241

Site US10012, Cincinnati

72205

Site US10014, Little Rock

94040

Site US10008, Mountain View

98115

Site US10006, Seattle

02114

Site US10002, Boston

10029-6574

Site US10004, New York

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02851277 - A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine | Biotech Hunter | Biotech Hunter